Keywords: علی کومامب; PCSK9 inhibitor; Alirocumab; Expanded use; Heterozygous familial hypercholesterolemia; Coronary heart disease; LDL-C; Statin intolerance; ODYSSEY;
مقالات ISI علی کومامب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: علی کومامب; alirocumab; chronic kidney disease; impaired renal function; LDL-C; PCSK9; safety;
Keywords: علی کومامب; Alirocumab; Hypercholesterolemia; LDLR; APOB; LDLRAP1;
Keywords: علی کومامب; Alirocumab; PCSK9; LDL-C; HeFH; Lipid therapy; Cholesterol; Maximally tolerated statin; Lipid lowering; Placebo-controlled; Double-blind;
Keywords: علی کومامب; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CVD; cardiovascular disease; CYP; cytochrome; EAS; European Atherosclerosis Society; FDA; Food and Drug Administration; FH; Familial hypercholesterolemia; GOF; gain of function; H
Keywords: علی کومامب; Monoclonal antibodies; Tocilizumab; Alirocumab; Evolocumab; Reticuloendothelial system; IL-6; PCSK9; Methotrexate; Simvastatin;
Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
Keywords: علی کومامب; Alirocumab; Type 2 diabetes mellitus; Cardiovascular risk; Cholesterol-lowering drugs; Low-density lipoprotein cholesterol; Proprotein convertase subtilisin/kexin type 9;
Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design
Keywords: علی کومامب; Alirocumab; Low-density lipoprotein cholesterol; Coronary artery disease; Monoclonal antibody;
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
Keywords: علی کومامب; PCSK9; Evolocumab; Alirocumab; Cardiovascular outcomes; Safety;
Proprotein Convertase Subtilisin Kexin 9 Inhibitors
Keywords: علی کومامب; PCSK9; Monoclonal antibodies; Evolocumab; Alirocumab; LDL-C; Hypercholesterolemia; Cardiovascular disease; Proprotein convertase subtilisin kexin 9;
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)
Keywords: علی کومامب; Alirocumab; PCSK9; LDL-C; South Korea; Taiwan; ODYSSEY phase 3; Hypercholesterolemia; Lipid lowering; Placebo-controlled; Maximally tolerated statin;
Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
Keywords: علی کومامب; PCSK9; Alirocumab; Cholesterol-lowering drugs; Low-density lipoprotein cholesterol; Coronary revascularization; Cardiovascular risk;
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: علی کومامب; Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Inhibidores de PCSK-9, efectos sobre el cLDL e implicaciones futuras: lo que se debe saber
Keywords: علی کومامب; ProproteÃna convertasa de subtilisina/kexina tipo 9; Inhibidores proproteÃna convertasa de subtilisina/kexina tipo 9; Evolocumab; Alirocumab; LipoproteÃna de baja densidad; Proprotein convertase subtilisin/kexin type 9; Proprotein convertase subtilisin
Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent)
Keywords: علی کومامب; Hypercholesterolemia; Alirocumab; PCSK9 inhibitor;
PCSK9 Inhibitors Show Value for Patients and the US Health Care System
Keywords: علی کومامب; alirocumab; cardiovascular disease; cholesterol; evolocumab; familial hypercholesterolemia; microsimulation; PCSK9;
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
Keywords: علی کومامب; PCSK9 inhibitors; Evolocumab; Alirocumab; Dyslipidemia; Hypercholesterolemia; Familial hypercholesterolemia; Statin intolerance; Lipid treatment guidelines;
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2Â years
Keywords: علی کومامب; Alirocumab; Injection; Adherence; Nonadherence; Hypercholesterolemia; Low-density lipoprotein cholesterol; Proprotein convertase subtilisin/kexin type 9 inhibitor;
The efficacy of anti-PCSK9 antibodies: Results from recent trials
Keywords: علی کومامب; Alirocumab; Anti-PCSK9 antibodies; Cardiovasvular disease; Evolocumab; PCSK9;
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Keywords: علی کومامب; PCSK9; Evolocumab; Alirocumab; LDL target; Lipid lowering therapy; Familial hypercholesterolemia;
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Keywords: علی کومامب; Heterozygous familial hypercholesterolemia; Low-density lipoprotein cholesterol; Cardiovascular risk; PCSK9 inhibitors; Alirocumab; Evolocumab;
New lipid therapies: PCSK9 inhibitors
Keywords: علی کومامب; LDL; LDL receptor; Atherothrombosis; Familial hyperlipidemia; Alirocumab; Evolocumab;
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
Keywords: علی کومامب; Alirocumab; Evolocumab; Ischemic stroke; Lipid lowering; Hypercholesterolemia; PCSK9 inhibitors;
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial
Keywords: علی کومامب; Alirocumab; Familial hypercholesterolemia; Low-density lipoprotein cholesterol; Monoclonal antibody; Proprotein convertase subtilisin/kexin type 9;
A review of PCSK9 inhibition and its effects beyond LDL receptors
Keywords: علی کومامب; PCSK9; Alirocumab; Evolocumab; Dyslipidemia;
Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
Keywords: علی کومامب; Alirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin;
A phase III randomized trial evaluating alirocumab 300Â mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Keywords: علی کومامب; Alirocumab; Cardiovascular risk; LDL-C; PCSK9; Placebo-controlled; Phase III; Randomized;
JCL roundtable: PCSK9 inhibitors in clinical practice
Keywords: علی کومامب; Lipoprotein; LDL-C; Alirocumab; Evolucumab; Cholesterol;
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Keywords: علی کومامب; ALT; alanine transaminase; ASO; antisense oligonucleotide; apoB; apolipoprotein B; CVD; cardiovascular disease; EGF; epidermal growth factor; LDL-C; low-density lipoprotein cholesterol; MTP; microsomal triglyceride transfer protein; PCSK9; proprotein conv
Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia
Keywords: علی کومامب; Alirocumab; PCSK9; Hypercholesterolemia; Statin; Cardiovascular risk; Low-density lipoprotein cholesterol; Monoclonal antibody;
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia
Keywords: علی کومامب; PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; Alirocumab; Evolocumab; Bococizumab;
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
Keywords: علی کومامب; Alirocumab; Ezetimibe; Hypercholesterolemia; PCSK9; Phase 3 clinical trial; Statin intolerance; Muscle symptoms; Statin myopathy;